Immune Netw.  2005 Mar;5(1):36-44. 10.4110/in.2005.5.1.36.

Immunocell Therapy for Lung Cancer: Dendritic Cell Based Adjuvant Therapy in Mouse Lung Cancer Model

• Lee SJ
• Kim MJ
• In SH
• Baek S
• Lee H

• KMID: 2150588
• DOI: http://doi.org/10.4110/in.2005.5.1.36

Abstract

BACKGROUND
The anti-tumor therapeutic effect of autologous tumor cell lysate pulsed-dendritic cells (DCs) was studied for non-immunogenic and immune suppressive lung cancer model. To test the possibility as an adjuvant therapy, minimal residual disease model was considered in mouse in vivo experiments. METHODS: Syngeneic 3LL lung cancer cells were inoculated intravenously into the C57BL/6 mouse. Autologous tumor cell (3LL) or allogeneic leukemia cell (WEHI-3) lysate pulsed-DCs were injected twice in two weeks. Intraperitoneal DC injection was started one day (MRD model) after tumor cell inoculation. Two weeks after the final DC injection, tumor formation in the lung and the tumor-specific systemic immunity were observed. Tumor-specific lymphocyte proliferation and the IFN-r secretion were analyzed for the immune monitoring. Therapeutic DCs were cultured from the bone marrow myeloid lineage cells with GM-CSF and IL-4 for 7 days and pulsed with tumor cell lysate for 18 hrs. RESULTS: Compared to the saline treated group, tumor formation was suppressed in 3LL tumor cell lysate pulsed-DC treated group, while 3LL-specific immune stimulation was minimum. WEHI-3-specific immune stimulation occurred in WEHI-3 lysate-pulsed DC treated group, which had no correlation with tumor regression. CONCLUSION: The data suggest the possible anti-tumor effect of cultured DCs as an adjuvant therapy for minimal residual disease state of lung cancer. The significance of immune modulation in DC therapy including the possible involvement of NK cell as well as antigen-specific cytotoxic T cell activity induction was discussed.

Keyword

Dendritic cells; anti-cancer immunotherapy; lung cancer

MeSH Terms

Animals
Bone Marrow
Dendritic Cells*
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Killer Cells, Natural
Leukemia
Lung Neoplasms*
Lung*
Lymphocytes
Mice*
Monitoring, Immunologic
Neoplasm, Residual
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4